[go: up one dir, main page]

GB201609925D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB201609925D0
GB201609925D0 GBGB1609925.1A GB201609925A GB201609925D0 GB 201609925 D0 GB201609925 D0 GB 201609925D0 GB 201609925 A GB201609925 A GB 201609925A GB 201609925 D0 GB201609925 D0 GB 201609925D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1609925.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Priority to GBGB1609925.1A priority Critical patent/GB201609925D0/en
Publication of GB201609925D0 publication Critical patent/GB201609925D0/en
Priority to PCT/GB2017/051615 priority patent/WO2017212233A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1609925.1A 2016-06-07 2016-06-07 Formulation Ceased GB201609925D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1609925.1A GB201609925D0 (en) 2016-06-07 2016-06-07 Formulation
PCT/GB2017/051615 WO2017212233A1 (en) 2016-06-07 2017-06-05 Formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609925.1A GB201609925D0 (en) 2016-06-07 2016-06-07 Formulation

Publications (1)

Publication Number Publication Date
GB201609925D0 true GB201609925D0 (en) 2016-07-20

Family

ID=56508190

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1609925.1A Ceased GB201609925D0 (en) 2016-06-07 2016-06-07 Formulation

Country Status (2)

Country Link
GB (1) GB201609925D0 (en)
WO (1) WO2017212233A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB201405891D0 (en) 2014-04-02 2014-05-14 Novabiotics Ltd Modified antimicrobial peptides
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds

Also Published As

Publication number Publication date
WO2017212233A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
GB2551985B (en) Novel formulation
GB201407934D0 (en) Formulation
GB201513010D0 (en) Novel formulation
IL274139A (en) Aerosolisable formulation
IL274719A (en) Formulation
GB201514758D0 (en) Formulation
GB201713724D0 (en) Formulation
GB201407384D0 (en) Formulation
RS62057B1 (en) Maropitant formulation
GB201608356D0 (en) Formulation
GB201706969D0 (en) Formulation
IL248835A0 (en) Ceritinib formulation
IL251362A0 (en) Formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201511301D0 (en) Formulation
GB201719464D0 (en) Formulation
GB201707615D0 (en) Formulation
PL3559185T3 (en) Clear-rinse formulation
GB2568045B (en) Formulation
GB201720808D0 (en) Formulation
GB201609925D0 (en) Formulation
GB201702058D0 (en) Formulation
GB201602048D0 (en) Formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)